Inpart monthly recap - July
New R&D trends report
Sustainable agriculture and food: R&D trends??
Discover the key priorities for industry-academia collaborations in sustainable food and agriculture in our latest R&D trends report.
These trends come from exclusive insights gathered through our partnering platform, Connect, and our recent Global Challenge campaign focused on sustainable food and agriculture.
Editor's picks from Connect
Innovative FAK inhibitors for solid tumors?
Biotech: Evariste (UK)?
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase involved in tumor development. At Evariste, researchers have identified potent FAK inhibitors with high selectivity and promising preclinical results, which are particularly effective when combined with other cancer therapies. The team are seeking co-development partners. ?
Next-generation semiconductors?
University: TransferTech Sherbrooke (Canada)?
This innovation introduces a process to create defect-free, compliant semiconductor substrates, enhancing the performance of high-performance devices like solar cells, lasers and detectors. The team are seeking investment and a partnership to commercialize the invention.?
Active Connect campaigns
Novo Nordisk?| Deadline 12th August
Novo Nordisk is looking for potential biotech and academic partners that are developing novel cell delivery solutions, with a specific interest in device, biomaterial, and formulation approaches.
Multinational pharmaceutical company (anonymous) | Deadline 16th September
A worldwide pharmaceutical manufacturer is seeking novel oral drug molecules for immunology and inflammation diseases, specifically those that act on clinically validated targets with biologic drugs in Phase 1 and beyond.
领英推荐
A biotechnology company specializing in genetic diseases (anonymous) | Deadline 23rd September
A leader in rare genetic disease therapies is seeking innovative treatments for hereditary haemorrhagic telangiectasia (HHT) types 1 and 2.
Upcoming event
Join us at the 2024 Inpart Summit in Lyon
The 2024 Inpart Summit, our annual User Group Meeting for top biopharma in-licensors, is taking place this September. ?
This year's event focuses on operational excellence in biopharma partnering, bringing together decision-makers from leading pharma and biotech companies. Attendees will share best practices on partnering data automation, business development, alliance management, and scouting, with opportunities for networking.
Biotech survey
Closing soon! Inform big pharma’s partnering strategies
As part of our efforts to make partnering more effective and efficient, we’re inviting you to complete our annual biotech survey, which will form the basis of our Partnering 2030 report.?
It will only take 10 minutes of your time and your responses will be kept strictly confidential and anonymous.?
TTO survey
Closing soon! What’s your experience of partnering with the top global R&D firms?
We are inviting the tech transfer community to share their experiences of partnering with top global R&D companies. Your responses will be featured anonymously in our 'Partnering 2030' report, helping the shape the future of R&D partnering.
Labiotech article
The ABC of biotech partnering
Discover eight different types of biotech partnerships, including what each one entails and its advantages and disadvantages.
Inpart is the trusted platform for scientific partnering. We provide solutions to facilitate, optimize, and track collaborations helping bring science to life.
Our online partnering network is used by over 17,000 scientists and decision-makers in industry and academia matched by their research priorities and interests.
Create a free account, identify new research and assets seeking partners, and establish new contacts for potential and future collaborations.